World's Best Scientists 2026 revealed!
Jean-Yves Pierga

Jean-Yves Pierga

D-Index & Metrics

Medicine

D-Index
82
Citations
26839
World Ranking
16037
National Ranking
524

Jean-Yves Pierga publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jean-Yves Pierga sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 553 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jean-Yves Pierga D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Yves Pierga sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jean-Yves Pierga is affiliated with the Institute Curie in France and has a substantial body of work primarily focused on oncology and cancer research. Their work spans multiple topics within medicine, biochemistry, genetics, and molecular biology, with a significant emphasis on breast cancer treatment and advanced breast cancer therapies.

The scientist's research covers several main topics including:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Cancer Cells and Metastasis
  • Cancer Immunotherapy and Biomarkers

The main fields of study for Jean-Yves Pierga involve:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, subfields include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Molecular Biology

Frequent co-authors in their research collaborations are:

  • François-Clément Bidard
  • Delphine Loirat
  • Enora Laas
  • Luc Cabel
  • Frédérique Berger

Publications have appeared regularly in venues such as:

  • Cancer Research
  • Cancers
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Cancer Research

Representative recent papers by Jean-Yves Pierga include:

  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, 2022, New England Journal of Medicine
  • 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age, 2021, The Lancet Oncology
  • Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial, 2022, The Lancet Oncology
  • Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer, 2024, New England Journal of Medicine
  • Clinical utility of circulating tumor cells: an update, 2020, Molecular Oncology

Best Publications

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets

  • A pooled analysis of bone marrow micrometastasis in breast cancer

    Stephan Braun;Florian D. Vogl;Bjørn Naume;Wolfgang Janni

  • Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

    François-Clément Bidard;François-Clément Bidard;Dieter Peeters;Tanja Fehm;Franco Nolé

  • Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study

    Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras

  • Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

    M. Kaufmann;G. Von minckwitz;H. D. Bear;Aman U Buzdar

  • 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

    Xavier Pivot;Gilles Romieu;Marc Debled;Jean-Yves Pierga

  • Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays

    Antoine Emmanuel Saliba;Laure Saias;Eleni Psychari;Nicolas Minc

  • Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

    Wolfgang J. Janni;Brigitte Rack;Leon W.M.M. Terstappen;Jean Yves Pierga

  • Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

    Jean-Yves Pierga;François-Clément Bidard;Claire Mathiot;Etienne Brain

  • Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients

    Jean-Yves Pierga;Charlyne Bonneton;Anne Vincent-Salomon;Patricia de Cremoux

  • Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

    François-Clément Bidard;Stefan Michiels;Sabine Riethdorf;Volkmar Mueller

  • 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Kevin Kalinsky;William E. Barlow;Julie R. Gralow;Funda Meric-Bernstam

  • Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

    François Clément Bidard;François Clément Bidard;Tanja Fehm;Michail Ignatiadis;Jeffrey B. Smerage

  • Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

    Ronald Lebofsky;Charles Decraene;Virginie Bernard;Maud Kamal

  • The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Massimo Cristofanilli;Jean Yves Pierga;James Reuben;Alfred Rademaker

  • 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    Martine Piccart;Laura J. van 't Veer;Coralie Poncet;Josephine M.N. Lopes Cardozo

  • Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study

    L. Cabel;F. Riva;V. Servois;A. Livartowski

  • High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

    J.-Y. Pierga;J.-Y. Pierga;D. Hajage;T. Bachelot;S. Delaloge

  • Single Circulating Tumor Cell Detection and Overall Survival in Non Metastatic Breast Cancer.

    F. Bidard;C. Mathiot;F. Mefti;S. Delaloge

Frequent Co-Authors

Véronique Diéras
Véronique Diéras Institute Curie
Suzette Delaloge
Suzette Delaloge Institut Gustave Roussy
Anne Vincent-Salomon
Anne Vincent-Salomon Institute Curie
Alain Fourquet
Alain Fourquet Institute Curie
Bernard Asselain
Bernard Asselain Institute Curie
Olivier Lantz
Olivier Lantz Institute Curie
Ivan Bièche
Ivan Bièche Institute Curie
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Xavier Sastre-Garau
Xavier Sastre-Garau Institute Curie
Mario Campone
Mario Campone Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens doors to a variety of rewarding healthcare roles beyond traditional MD programs. Many students now pursue online graduate degrees to specialize and advance their careers while maintaining flexibility.

For instance, if you’re interested in mental health, check out online psych np programs. These programs offer a direct route to becoming a Psychiatric Mental Health Nurse Practitioner, a highly in-demand role in healthcare.

Administrative roles are also growing quickly in healthcare. You can consider enrolling in one of the cheapest mha programs online to gain skills in leadership, policy, and operations.

It’s important to evaluate the mha degree cost as you plan your investments in education. This helps you make informed decisions about affordability and return on investment.

For nursing professionals seeking top credentials, pursuing the cheapest dnp (Doctor of Nursing Practice) online can lead to advanced clinical, leadership, or academic positions.

Best Scientists Citing Jean-Yves Pierga

Trending Scientists